The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMW 2021 | COVID-19 in myeloma: what have we learnt?
Joaquin Martinez-Lopez, MD, PhD, of the Universidad Complutense de Madrid, Madrid, Spain, talks on the impact that the COVID-19 pandemic has had on the treatment and management of patients with multiple myeloma, and discusses what can be learnt from this. Dr Martinez-Lopez shares some preliminary data from studies investigating the severity and clinical outcomes for patients with multiple myeloma. Another study looked at real-world data from 80,000 patients globally, which found that patients with multiple myeloma were more likely to be diagnosed with COVID-19. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
Disclosures
Joaquin Martinez-Lopez, MD, PhD, has received grant support from BMS; and has performed consultancy work for BMS, Janssen, Novartis, GSK, Incyte, Roche and Astellas.
